A Randomized Phase Ii Study Comparing Cabazitaxel/Prednisone To Cabazitaxel Alone In Docetaxel-Pretreated Men With Metastatic Castration Resistant Prostate Cancer (Mcrpc): The Cabacare Trial.

Carlo Buonerba,Francesco Grillone,Sabrina Rossetti,Lorenzo Livi,Mario Scartozzi,Pierosandro Tagliaferri,Dario Bruzzese,Luca Scafuri,Vittorio Riccio,Ferdinando Costabile,Davide Bosso,Simona Iaccarino,Gaetano Facchini,Simone Carrano,Michela Izzo,Michele Caraglia,Sabino De Placido,Giuseppe di Lorenzo

JOURNAL OF CLINICAL ONCOLOGY（2019）

Cited 0|Views68

No score

Abstract

TPS345Background: In the TROPIC trial, cabazitaxel (CAB) plus daily prednisone (PDN) was associated with a significant advantage in OS and PFS in docetaxel (DOC)-pretreated patients (Pts). Whether ...

Translated text

Key words

resistant prostate cancer,prostate cancer,cabazitaxel/prednisone,docetaxel-pretreated

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined